ArticleExperimental & molecular medicine2026
Sphingosine-1-phosphate receptor 1 signaling stimulates human pluripotent stem cell-derived cardiomyocyte differentiation and maturation.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The development of human-relevant in vitro cardiac models is essential for evaluating cardiotoxicity and drug efficacy. Although wingless-related integration site signaling-based protocols have enabled cardiomyocyte (CM) differentiation from pluripotent stem cells, issues such as low efficiency, immature phenotype, and variability across cell lines remain to be resolved. Here, we present an improved differentiation strategy that robustly enhances both the efficiency and functional maturity of CMs, comparable to the functional characteristics of human adult myocardial tissue. Although fetal bovine serum enhanced differentiation, we disclosed that the interaction between sphingosine-1-phosphate (S1P) and its receptor S1PR1 is a major contributor. Gene-based and protein-based analyses and electrophysiological analysis via multielectrode array confirmed that activation of S1PR1 using S1P or its agonist SEW2871 increased the generation of spontaneously beating CMs, whereas S1PR1-deficient pluripotent stem cells exhibited impaired differentiation and functional maturity of S1P-S1PR1-derived CMs. Furthermore, we observed improved cardiac function and reduced fibrosis in a myocardial infarction mouse model induced by left descending artery ligation following transplantation of CMs differentiated more robustly by treatment with S1P or SEW2871. Collectively, S1PR1 activator-treated CMs offer a cost-effective platform for drug discovery and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.